Re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Active Surveillance plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128-36

被引：1

作者：

Rivas, Juan Gomez ^{[1
,2
]}

Gandaglia, Giorgio ^{[2
,3
]}

Montorsi, Francesco ^{[2
,3
]}

机构：

[1] Hosp Clin San Carlos, Dept Urol, Calle Prof Martin Lagos S-N, Madrid 28040, Spain

[2] European Assoc Urol, Young Acad Urologists, Arnhem, Netherlands

[3] Univ Vita Salute San Raffaele, IRCCS San Raffaele Hosp, Div Oncol, Unit Urol, Milan, Italy

来源：

EUROPEAN UROLOGY OPEN SCIENCE | 2022年 / 46卷

关键词：

ANDROGEN DEPRIVATION THERAPY;

D O I：

10.1016/j.euros.2022.09.022

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：135 / 136

页数：2

共 5 条

[1] Reply to Juan Gomez Rivas, Giorgio Gandaglia, and Francesco Montorsi's Letter to the Editor re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Enzalutamide Monotherapy vs Active Surveillance in Patients with Low- risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128-36
Shore, Neal D.
[J]. EUROPEAN UROLOGY OPEN SCIENCE, 2022, 46 : 145 - 146
[2] Re: Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial
Kesch, Claudia
Hadaschik, Boris A.
[J]. EUROPEAN UROLOGY, 2022, 82 (05) : 572 - 572
[3] Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer The ENACT Randomized Clinical Trial
Shore, Neal D.
Renzulli, Joseph
Fleshner, Neil E.
Hollowell, Courtney M. P.
Vourganti, Srinivas
Silberstein, Jonathan
Siddiqui, Rizwan
Hairston, John
Elsouda, Dina
Russell, David
Cooperberg, Matthew R.
Tomlins, Scott A.
[J]. JAMA ONCOLOGY, 2022, 8 (08) : 1128 - 1136
[4] Re: Enzalutamide Monotherapy vs. Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial
Taneja, Samir S.
[J]. JOURNAL OF UROLOGY, 2023, 209 (03): : 636 - 637
[5] Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-Risk or Intermediate-Risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial (Jun, 10.1001/jamadermatol.2022.1641, 2022)
Shore, N. D.
Renzulli, J.
Fleshner, N. E.
[J]. JAMA ONCOLOGY, 2022, 8 (08) : 1225 - 1225

← 1 →